Streamline your EMR experience

Introducing an easier way to test, report and share. Simplify your testing workflow with Myriad’s EMR integrations.











You agree to be contacted with newsletters, marketing or promotional materials and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in any email we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Policy.

Hidden Fields











Hidden test fields



Order tests and view results in one place

Expanding access to more EMRs

Genetic test ordering and results are now where you need them, when you need them. Myriad offers electronic medical record (EMR) integration, allowing providers and their patients instant access to important health information.

Order tests and view results in one place

Expanding access to more EMRs

Genetic test ordering and results are now where you need them, when you need them. Myriad offers electronic medical record (EMR) integration, allowing providers and their patients instant access to important health information.

Supported EMR platforms

Myriad can support most EMR platforms you currently use. We offer native integration with most EMR platforms and can build customizable solutions for others.

Logos of Myriad Genetics and Epic

Epic and Myriad partnership

Myriad has partnered with Epic to improve efficiencies and increase access for more than 250 million patients. Our native integration with Epic is simple to deploy, requiring minimal technical lift and no incremental implementation costs.

Myriad results on Epic’s Care Everywhere network

Clinicians and patients will have access to their Myriad results across Epic’s Care Everywhere network of health systems, allowing for:

    Coordinated care
    Seamless coordination across the patient’s care team

    Real-time access
    Real-time secure sharing of genetic insights

    Open communication
    Removal of barriers in patient care and communication

ONCOEMR logoc

Flatiron Health and Myriad partnership

Myriad has partnered with Flatiron Health to provide an integration to OncoEMR®. By creating a streamlined, end-to-end workflow for germline testing in OncoEMR, clinicians will have access to the results they need at point-of-care, facilitating personalized treatment decisions for patients while reducing administrative burdens and improving turnaround times for results.

How to integrate Myriad into your EMR

Myriad makes the integration process simple for you. We assign a dedicated project team to work directly with your staff and the EMR vendor to ensure a smooth transition.

Step 1:
Notify Myriad

Let your sales rep know you’re interested in integrating with Myriad.

Step 2:
Provide information

We will collect information and submit a request to the Myriad Clinical Integrations team.

Step 3:
Plan and timeline

The Myriad team will coordinate with you and your sales rep to create a plan and timeline.

Myriad Genetics tests and screens

We offer industry-leading genetic insights with a seamless EMR experience. The following Myriad tests and screens are available as bidirectional interfaces (ordering + resulting) within your EMR platform.

BRACAnalysis CDx product signature

BRACAnalysis CDx® is an FDA-approved test used to identify patients with germline BRCA1/2 mutations who may be eligible for certain targeted therapies.

  • For patients with breast, ovarian, pancreatic or prostate cancer
  • FDA approved, accurate germline BRCA1/2 testing to identify eligibility for targeted therapies
  • No family history is required to meet genetic testing guidelines
Foresight® Carrier Screen product signature

Foresight® Carrier Screen detects a couple’s risk of passing down serious, inheritable health conditions to their child to guide informed planning and preparation.

  • Identify the 1 in 22 couples at risk for pregnancies with serious, prevalent, or clinically-actionable inherited conditions
  • 99% detection rate across ethnicities for the vast majority of the 176 genes on our panel2
GeneSight® Mental Health Medication Test product signature

The GeneSight® Psychotropic test analyzes how a patient’s genes may affect their outcomes with medications commonly prescribed to treat depression, anxiety, ADHD and other mental health conditions.

  • Delivers genetic insights that can help inform your mental health treatment plans
  • Access to test significantly improved remission and response rates compared to treatment as usual3
  • Ordered by tens of thousands of clinicians for 2MM+ patients
MyGeneHistory™ product signature
  • Online family history assessment identifies patients for genetic testing with MyRisk
  • Natively integrated with the athena EMR platform
  • Efficient end-to-end workflows for your staff and patients
MyRisk™ product signature

MyRisk® Hereditary Cancer Test is a multi-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on 11 primary cancer sites.

  • All-in-one personalized cancer risk assessment
  • Evaluates 48 genes associated with 11 different hereditary cancers
  • RiskScore® predicts a patient’s 5-year and lifetime risk of developing breast cancer
Prequel®Prenatal Screen product signature

Designed for everyone regardless of ancestry, BMI, or ability to pay, the Prequel® Prenatal Screen can determine if a pregnancy is at an increased risk for a wide variety of chromosomal conditions as early as eight weeks.

  • The only non-invasive prenatal screening (NIPS) that uses AMPLIFY™ technology
  • 99.9% result delivery on the first draw at 10 weeks1
  • Accessible and reliable for everybody, regardless of BMI, ancestry, or ability to pay
References
  1. Welker et al. High-throughput fetal fraction amplification increases analytical performance of noninvasive prenatal screening. Genet Med 23, 443–450 (2021)
  2. Myriad Genetics. Data on file. https://myriad-library.s3.amazonaws.com/mwh/disease-detection-fact-sheet.pdf
  3. Greden JF, Parikh SV, Rothschild AJ, et al. Impact of pharmacogenomics on Clinical Outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. Journal of Psychiatric Research. 2019;111:59-67. doi:10.1016/j.jpsychires.2019.01.003; Oslin DW, Lynch KG, Shih M-C, et al. Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder. JAMA. 2022;328(2):151. doi:10.1001/jama.2022.9805; Brown L, Vranjkovic O, Li J, et al. The clinical utility of combinatorial pharmacogenomic testing for patients with depression: A meta-analysis. Pharmacogenomics. 2020;21(8):559-569. doi:10.2217/pgs-2019-0157